Insider Transaction Report for Andrew Booth

Andrew Booth, Chief Financial Officer of AbCellera Biologics Inc. (ABCL), reported a series of transactions on June 3, 2026. Booth acquired 250,000 common shares under a stock option, with a purchase price of $0.19 per share, increasing his direct holdings to 445,600 shares. Additionally, an option to purchase 250,000 common shares was exercised, with an exercise price of $0.19 per share. Following these transactions, Booth holds 8,501,849 shares underlying this option. The report also notes that 130,959 shares are held indirectly by his spouse. These options vest over a six-year period, with the first tranche vesting on June 15, 2017.